CA2293706C - Nouveaux composes d'uree n-substitues inhibiteurs de la farnesyl transferase - Google Patents

Nouveaux composes d'uree n-substitues inhibiteurs de la farnesyl transferase Download PDF

Info

Publication number
CA2293706C
CA2293706C CA002293706A CA2293706A CA2293706C CA 2293706 C CA2293706 C CA 2293706C CA 002293706 A CA002293706 A CA 002293706A CA 2293706 A CA2293706 A CA 2293706A CA 2293706 C CA2293706 C CA 2293706C
Authority
CA
Canada
Prior art keywords
aryl
compound
alkyl
heterocycloalkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002293706A
Other languages
English (en)
Other versions
CA2293706A1 (fr
Inventor
Stacy Remiszewski
Alan K. Mallams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CA2293706A1 publication Critical patent/CA2293706A1/fr
Application granted granted Critical
Publication of CA2293706C publication Critical patent/CA2293706C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés d'urée halogéno N-substitués et des compositions pharmaceutiquement acceptables de formules (1.0) ainsi que leurs sels ou solvates pharmaceutiquement acceptables, qui sont des inhibiteurs de l'enzyme farnésyl transférase. La présente invention concerne également une méthode d'inhibition de la fonction Ras et donc de la croissance anormale des cellules. Cete méthode, qui consiste à administrer le nouveau composé d'urée halogéno N-substitué à un système biologique permet notamment d'inhiber la croissance anormale des cellules chez des mammifères tel que l'homme.
CA002293706A 1997-06-17 1998-06-15 Nouveaux composes d'uree n-substitues inhibiteurs de la farnesyl transferase Expired - Fee Related CA2293706C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87704997A 1997-06-17 1997-06-17
US08/877,049 1997-06-17
PCT/US1998/011507 WO1998057948A1 (fr) 1997-06-17 1998-06-15 Nouveaux composes d'uree n-substitues inhibiteurs de la farnesyl transferase

Publications (2)

Publication Number Publication Date
CA2293706A1 CA2293706A1 (fr) 1998-12-23
CA2293706C true CA2293706C (fr) 2008-11-18

Family

ID=25369144

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002293706A Expired - Fee Related CA2293706C (fr) 1997-06-17 1998-06-15 Nouveaux composes d'uree n-substitues inhibiteurs de la farnesyl transferase

Country Status (14)

Country Link
EP (1) EP0989979A1 (fr)
JP (1) JP2002506444A (fr)
KR (1) KR20010013881A (fr)
CN (1) CN1267291A (fr)
AR (1) AR013094A1 (fr)
AU (1) AU8253598A (fr)
CA (1) CA2293706C (fr)
CO (1) CO4940458A1 (fr)
HU (1) HUP0002954A3 (fr)
IL (1) IL133389A0 (fr)
NZ (1) NZ501571A (fr)
PE (1) PE82799A1 (fr)
WO (1) WO1998057948A1 (fr)
ZA (1) ZA985205B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
CA2424797C (fr) * 2000-10-05 2009-12-29 George Q. Daley Methodes d'induction de l'apoptose de cellules cancereuses et de la regression de tumeurs
CA2550012A1 (fr) * 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Derives d'uree, processus de production correspondant et utilisation
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
TW201524952A (zh) * 2013-03-15 2015-07-01 Araxes Pharma Llc Ｋｒａｓ ｇ１２ｃ之共價抑制劑
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US9862701B2 (en) 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
EP3280708B1 (fr) 2015-04-10 2021-09-01 Araxes Pharma LLC Composés quinazolines substitués et procédés pour leur utilisation
MX2017013275A (es) 2015-04-15 2018-01-26 Araxes Pharma Llc Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos.
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356359B1 (fr) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibiteurs de protéines kras portant la mutation g12c
WO2017058902A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines mutantes kras g12c
WO2017058915A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines mutantes kras g12c
WO2017058768A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058805A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
WO2017070256A2 (fr) 2015-10-19 2017-04-27 Araxes Pharma Llc Méthode de criblage d'inhibiteurs de ras
CA3005089A1 (fr) 2015-11-16 2017-05-26 Araxes Pharma Llc Composes quinazoline substitues en position 2 comprenant un groupe heterocyclique substitue et leur methode d'utilisation
WO2017100546A1 (fr) 2015-12-09 2017-06-15 Araxes Pharma Llc Procédés de préparation de dérivés de quinazoléine
WO2017172979A1 (fr) 2016-03-30 2017-10-05 Araxes Pharma Llc Composés quinazoline substitués et procédés d'utilisation
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018064510A1 (fr) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibiteurs de protéines mutantes kras g12c
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573970A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573967A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Composés hétéro-hétéro-bicycliques fusionnés et leurs procédés d'utilisation
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
BR112019024674A2 (pt) 2017-05-25 2020-06-16 Araxes Pharma Llc Inibidores covalentes da kras
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
CN111960990A (zh) * 2020-07-23 2020-11-20 宿迁联盛科技股份有限公司 一种助剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
SK86198A3 (en) * 1995-12-22 1999-02-11 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
DE69732123T2 (de) * 1996-09-13 2005-12-08 Schering Corp. Trizyklische Verindung mit Farnesylproteintransferase inhibierender Wirkung
SK33599A3 (en) * 1996-09-13 2000-03-13 Schering Corp Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase

Also Published As

Publication number Publication date
CA2293706A1 (fr) 1998-12-23
HUP0002954A2 (hu) 2001-06-28
PE82799A1 (es) 1999-08-26
KR20010013881A (ko) 2001-02-26
ZA985205B (en) 1998-12-15
JP2002506444A (ja) 2002-02-26
CO4940458A1 (es) 2000-07-24
HUP0002954A3 (en) 2002-11-28
AR013094A1 (es) 2000-12-13
IL133389A0 (en) 2001-04-30
EP0989979A1 (fr) 2000-04-05
WO1998057948A1 (fr) 1998-12-23
CN1267291A (zh) 2000-09-20
AU8253598A (en) 1999-01-04
NZ501571A (en) 2002-02-01

Similar Documents

Publication Publication Date Title
CA2293706C (fr) Nouveaux composes d'uree n-substitues inhibiteurs de la farnesyl transferase
US6358968B1 (en) N-substituted urea inhibitors of farnesyl-protein transferase
WO1998057946A1 (fr) Composes tricycliques de carboxy piperidylacetamide utilises pour inhiber une fonction g-proteine et traiter des maladies proliferatives (inhibiteurs de farnesyl proteine transferase)
EP0927178B1 (fr) Composes tricycliques inhibant la fonction de la proteine g et traitant les maladies proliferantes
CA2293672C (fr) Derives tricycliques de ceto-amides s'utilisant comme inhibiteurs de la transferase de proteine de farnesyl
EP0927181A1 (fr) Composes tricycliques servant a inhiber la farnesyl-proteine transferase
CA2293358C (fr) Sulfonamides tricycliques servant a inhiber la farnesyl-proteine transferase
AU5196698A (en) Compounds useful for inhibition of farnesyl protein transferase
US6218401B1 (en) Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
US6426352B1 (en) Sulfonamide inhibitors of farnesyl-protein transferase
CA2261724C (fr) Nouvelles n-cyano-imines tricycliques utiles en tant qu'inhibiteurs de la farnesyle transferase
CA2293553C (fr) Composes tricycliques aminooxyamide inhibiteurs de farnesyl-proteine transferase
MXPA99012069A (en) Novel n-substituted urea inhibitors of farnesyl-protein transferase
EP0927179B1 (fr) Derives substitues de la benzocycloheptapyridine utiles pour l'inhibition de la farnesyl transferase
CA2293373C (fr) Derives de benzo(5,6)cyclohepta(1,2b)pyridine s'utilisant comme inhibiteurs de transferase de proteine de farnesyl
EP0993460A1 (fr) Derives de benzo(5,6)cyclohepta(1,2-b)pyridine inhibiteurs de la farnesyl proteine transferase
CA2293549C (fr) Composes tricycliques substitues de phenyle servant a inhiber la farnesyl-proteine transferase
MXPA99012080A (en) Novel aminooxyamide tricyclic inhibitors of farnesylprotein transferase
MXPA99012084A (en) Novel tricyclic sulfonamide inhibitors of farnesyl-protein transferase
MXPA99012087A (en) Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed